TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30255228
Drug: Potassium bicarbonate
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium bicarbonate (KHCO3) supplementation (90 mmol daily) during bed rest
Study: 28751663
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate long-acting injectables (1-monthly and 3-monthly)
Study: 28751663
Drug: Switching from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching from oral antipsychotics to long-acting injectables
Study: 23819342
Drug: Atenolol (68.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (68.7 ± 4.17 mg/day)
Study: 23819342
Drug: Amlodipine (5.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5.5 ± 0.34 mg/day)
Study: 12612232
Drug: Minimal feeding
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal feeding volumes (20 mL/kg/d for the first 10 days)
Study: 12612232
Drug: Advancing feeding
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advancing feeding volumes (20 mL/kg/d on day 1, increased by 20 mL/kg/d up to 140 mL/kg/d)
Study: 10839897
Drug: Intravenous clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous clonidine (1.5 microg/kg)
Study: 10839897
Drug: Intravenous clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous clonidine (3.0 microg/kg)
Study: 10839897
Drug: Intravenous clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous clonidine (1.5 and 3.0 microg/kg)
Study: 9089424
Drug: Intravenous neu‐metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous neu‐metoclopramide (1.8 mg/kg)
Study: 9089424
Drug: Intramuscular neu‐metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular neu‐metoclopramide (1.8 mg/kg)
Study: 9089424
Drug: Intravenous metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metoclopramide (1.8 mg/kg)
Study: 9089424
Drug: Intravenous neu‐metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous neu‐metoclopramide
Study: 9089424
Drug: Intramuscular neu‐metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular neu‐metoclopramide
Study: 8262291
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg prostaglandin E2 (PGE2), repeated daily if necessary (group 1)
Study: 8262291
Drug: 0.50 mg
Normalized name: EVEROLIMUS 0.50 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.50 mg prostaglandin E2 (PGE2) (group 2)
Study: 25518484
Drug: Mouth rinsing
Normalized name: phenol
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mouth rinsing with 50 ml of 1% urea solution
Study: 25518484
Drug: Mouth rinsing
Normalized name: phenol
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mouth rinsing with various concentrations and amounts of urea solution
Study: 20388471
Drug: Kuntai Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kuntai Capsule (6 g three times a day)
Study: 20388471
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen (CEE) (0.3 mg and 0.6 mg alternately once a day, average dose of 0.45 mg/d)
Study: 11880065
Drug: Single-dose gatifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose gatifloxacin (400 mg)
Study: 11880065
Drug: 3-day gatifloxacin
Normalized name: gatifloxacin 3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day gatifloxacin (200 mg daily)
Study: 11880065
Drug: 3-day ciprofloxacin
Normalized name: ciprofloxacin 3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day ciprofloxacin (100 mg twice daily)
Study: 7747859
Drug: Edrophonium 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 0.75 mg.kg‐1 and atropine 0.015 mg.kg‐1
Study: 2202550
Drug: Immediate-release indomethacin
Normalized name: indomethacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release indomethacin capsules, 25 mg given 3-times daily
Study: 25981871
Drug: Biological explanation
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological explanation
Study: 23736793
Drug: Autologous platelet-rich
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous platelet-rich plasma (PRP) treatment (9 injections over 1 year, 2.0 to 2.5-fold platelet concentration)
Study: 14764389
Drug: Perindopril 2
Normalized name: perindopril 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 2 mg/Indapamide 0.625 mg (very low dose combination therapy)
Study: 14764389
Drug: Perindopril plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril plus Indapamide (very low doses)
Study: 7710569
Drug: Calcium gluconate
Normalized name: Calcium Gluconate
DrugBank: Calcium gluconate (DB11126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium gluconate (100 mg/kg)
Study: 2551520
Drug: 3% 2-chloroprocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% 2-chloroprocaine (2-CP) with 3 ml 0.9% NaCl (Control)
Study: 333341
Drug: Mucolytic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucolytic and decongestive treatment
Study: 333341
Drug: Previous antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous antibiotic treatment for acute otitis media
Study: 28827011
Drug: Rotigotine (4-16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine (4-16 mg/24 h)
Study: 23433094
Drug: CHD patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHD patients without acute inflammation and overt iron deficiency (C reactive protein <1 mg/dl and ferritin >30 ng/ml; n=86)
Study: 17093176
Drug: Iodized peanut
Normalized name: calcium iodized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodized peanut oil (P200, P400, P800 mg I)
Study: 17093176
Drug: Iodized poppy
Normalized name: calcium iodized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodized poppy seed oil (PS400 mg I)
Study: 17093176
Drug: Iodized peanut
Normalized name: calcium iodized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodized peanut oil (P400 mg I)
Study: 15317642
Drug: slow-release bupropion
Approvals — FDA: no, EMA: no, PMDA: no
Description: slow-release bupropion 150 mg b.i.d.
Study: 11558493
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil monotherapy
Study: 11558493
Drug: Calcineurin-inhibitor therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcineurin-inhibitor therapy (ciclosporin or tacrolimus)
Study: 8013271
Drug: Moguisteine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moguisteine (200 mg t.i.d. for four days)
Study: 23729104
Drug: Surgery, radiotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery, radiotherapy, and additional chemotherapy
Study: 18512224
Drug: Weekly regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly regimen (paclitaxel 100 mg/m² weekly for 3 of 4 weeks; carboplatin AUC = 6 mg/mL.min every 4 weeks)
Study: 18512224
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen (paclitaxel 225 mg/m² every 3 weeks; carboplatin AUC = 6 mg/mL.min on Day 1 every 21 days)
Study: 10989734
Drug: Fosinopril 20
Normalized name: fosinopril 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril 20 mg/day for 8 weeks, with the possibility to increase treatment to Fosinopril + hydrochlorothiazide after 4 weeks
Study: 8788082
Drug: Nicotine dermal
Normalized name: Dermal-Soothe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine dermal plaster (21 mg/24 h or 14 mg/24 h)
Study: 1634054
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg 5-ASA three times daily (n = 64)
Study: 6229176
Drug: Vancomycin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (15 mg/kg/dose)
Study: 30126618
Drug: Oral methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methylprednisolone (96 mg immediately after treatment followed by 48 mg each day for 5 consecutive days)
Study: 24692737
Drug: Pilocarpine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilocarpine (5 mg pilocarpine three times daily, n=5)
Study: 24692737
Drug: Control (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (saline solution intake, n=6)
Study: 15788496
Drug: ACVBP (doxorubicin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone) plus sequential consolidation
Study: 10826429
Drug: Bowel preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowel preparation with oral polyethylene glycol electrolyte solution
Study: 1641820
Drug: 0.25 mg/kg/24
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg/24 h alteplase
Study: 1641820
Drug: 0.5 mg/kg/24
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg/24 h alteplase
Study: 30644260
Drug: Short-segment fixation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-segment fixation combined with vertebral reconstruction (treatment group)
Study: 27247511
Drug: Dexmedetomidine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1.0 µg/kg IV loading dose followed by 0.5 µg/kg/hr infusion)
Study: 20872929
Drug: Memantine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (20 mg per day) for 24 weeks
Study: 18065586
Drug: Daily iron
Normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily iron (DI) foodLETs (10 mg)
Study: 18065586
Drug: Daily multiple-micronutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily multiple-micronutrients (DMM) foodLETs (10 mg Fe)
Study: 18065586
Drug: Weekly multiple-micronutrient
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly multiple-micronutrient (WMM) foodLETs (20 mg Fe)
Study: 1371665
Drug: Aprotinin (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (total dose, 6 to 7 x 10(6) KIU)
Study: 30522524
Drug: DHP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHP treatment
Study: 27230605
Drug: nab-P/C (nab-paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: nab-P/C (nab-paclitaxel 100 mg/m2 on days 1, 8, and 15 + carboplatin at AUC 6 mg·min/mL on day 1 every 3 weeks)
Study: 27230605
Drug: sb-P/C (solvent-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: sb-P/C (solvent-based paclitaxel 200 mg/m2 on day 1 + carboplatin at AUC 6 mg·min/mL on day 1 every 3 weeks)
Study: 8699062
Drug: Acyclovir (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (800 mg 5 times/day) and prednisolone (0.7 mg/kg for the first 4 days, reduced by 0.1 mg/kg on consecutive days for another 6 days)
Study: 1896168
Drug: Timolol (topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol (topical medication)
Study: 28168204
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg Pioglitazone
Study: 25526875
Drug: Metformin 850
Normalized name: metFORMIN 850 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 850 mg daily for 7 days, then 850 mg twice a day for the next 5 weeks
Study: 19298459
Drug: Pioglitazone (15-45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (15-45 mg day(-1)) added to sulfonylurea
Study: 19298459
Drug: Pioglitazone (15-45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (15-45 mg day(-1)) added to metformin
Study: 19298459
Drug: Gliclazide (80-320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide (80-320 mg day(-1)) + metformin
Study: 19298459
Drug: Gliclazide (80-320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide (80-320 mg day(-1)) + pioglitazone
Study: 12145995
Drug: 5'‐DFUR 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5'‐DFUR 600 mg/body/day for 6 months and TAM 20 mg/body/day for 2 years (Group A)
Study: 12145995
Drug: 5'‐DFUR 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5'‐DFUR 600 mg/body/day for 2 years and TAM 20 mg/body/day for 2 years (Group B)
Study: 1968323
Drug: atenolol 100
Normalized name: atenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol 100 mg od
Study: 1968323
Drug: propranolol (slow
Approvals — FDA: no, EMA: no, PMDA: no
Description: propranolol (slow release) 160 mg od
Study: 1968323
Drug: pindolol 5
Normalized name: pindolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pindolol 5 mg tid
Study: 1968323
Drug: nebivolol 5
Normalized name: nebivolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nebivolol 5 mg od
Study: 27342579
Drug: Sucroferric oxyhydroxide
Normalized name: Sucroferric Oxyhydroxide
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucroferric oxyhydroxide 1.0-3.0 g/day
Study: 27342579
Drug: Sevelamer carbonate
Normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevelamer carbonate 2.4-14.4 g/day
Study: 19267352
Drug: Multi-peptide vaccination
Normalized name: Multi-peptide vaccination
DrugBank: CoVac-1 (DB16429)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-peptide vaccination with 11 HLA‐A*0201‐restricted and two HLA class II synthetic peptides, administered subcutaneously for 18 months or until PSA progression, combined with various adjuvants including imiquimod, GM‐CSF, mucin‐1‐mRNA/protamine complex, and local hyperthermia.
Study: 19267352
Drug: Imiquimod and
Normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imiquimod and mucin‐1‐mRNA/protamine complex as adjuvants (both are Toll‐like receptor‐7 agonists).
Study: 11725730
Drug: OC containing
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC containing 0.030 mg of ethinyl estradiol (EE) and 0.15 mg of desogestrel (Group A)
Study: 11725730
Drug: OC containing
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC containing 0.020 mg of ethinyl estradiol (EE) and 0.15 mg of desogestrel (Group B)
Study: 9164358
Drug: Theophylline (extended-release)
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline (extended-release)
Study: 2959198
Drug: Amikacin-ceftazidime-teicoplanin treatment
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amikacin-ceftazidime-teicoplanin treatment
Study: 15897360
Drug: Amlodipine (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (one of the antihypertensives)
Study: 15897360
Drug: Ramipril and
Normalized name: ramipril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril and Metoprolol (other antihypertensives)
Study: 12324674
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide 400 micro g twice daily
Study: 22583583
Drug: Delayed rebonding
Normalized name: SKIN BOND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed rebonding after one month in a simulated oral environment
Study: 20869557
Drug: 0.3 percent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 percent solution‐based ciprofloxacin (Ciloxan)
Study: 15851401
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (daily antioxidant powder containing riboflavin, vitamin E, selenium, and N-acetylcysteine for 20 weeks)
Study: 12844385
Drug: Fish-oil capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish-oil capsules containing 400 mg DHA/g (200 mg/d) (n=50)
Study: 12844385
Drug: Placebo containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo containing 810 mg oleic acid/g (400 mg/d) (n=50)
Study: 8783998
Drug: Direct infusion
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct infusion of shed mediastinal blood (Group I)
Study: 6539812
Drug: Metoclopramide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (2 mg/kg intravenous every two hours for five doses)
Study: 6539812
Drug: Haloperidol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (3 mg intravenous every two hours for five doses)
Study: 29199384
Drug: LED therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LED therapy (658 nm) with 40 mW, 7 J/cm2 on every other day
Study: 26050706
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg oral N-acetylcysteine (NAC) twice daily during AmB treatment
Study: 22275504
Drug: Autologous CIK
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous CIK cell immunotherapy
Study: 22275504
Drug: Interleukin-2 treatment
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interleukin-2 treatment combination with IFN-α-2a
Study: 20637967
Drug: 21-mg/24-hour patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21-mg/24-hour patch
Study: 20637967
Drug: 25-mg/16-hour patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25-mg/16-hour patch
Study: 20637967
Drug: 21-mg/24-hour patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21-mg/24-hour patch (16-hour application time)
Study: 16466061
Drug: Oral zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zinc sulphate (50 mg of elemental zinc)
Study: 9413354
Drug: Eflornithine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eflornithine (0.5 to 3 g/m2 daily for 6 to 12 months in phase 1; 0.5 g/m2 for 12 months in phase 2)
Study: 3555956
Drug: Semi-synthetic human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semi-synthetic human insulin
Study: 3555956
Drug: Treatment periods
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment periods in chronological order
Study: 30666366
Drug: SOMS-guided mobility
Normalized name: Wal-Som
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SOMS-guided mobility treatment with a facilitator
Study: 24606242
Drug: NoRx (open-label
Approvals — FDA: no, EMA: no, PMDA: no
Description: NoRx (open-label 'no treatment')
Study: 21704889
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with standardized house dust mite extract
Study: 18187431
Drug: Glucomannan (Propol)
DrugBank: Konjac mannan (DB14963)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucomannan (Propol) 2 x 1.3 gr daily for two months
Study: 18187431
Drug: Placebo powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo powder daily for two months
Study: 15210522
Drug: Embryonic tissue
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Embryonic tissue implants
Study: 11454015
Drug: Gemfibrozil (GF),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil (GF), 600 mg b.i.d. for 12 weeks
Study: 7823273
Drug: Guided tissue
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided tissue regeneration with metronidazole gel (25%, 250 mg/g)
Study: 7823273
Drug: Guided tissue
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided tissue regeneration without metronidazole gel (control)
Study: 2898321
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg metaclazepam per day for 13 days
Study: 2898321
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg bromazepam per day for 13 days
Study: 21316208
Drug: DHA+AA (220
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA+AA (220 mg/day)
Study: 18494204
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy in open cholecystectomy
Study: 17159063
Drug: CRT-defibrillator therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRT-defibrillator therapy
Study: 17159063
Drug: CRT therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRT therapy
Study: 17159063
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of neurohormonal antagonists
Study: 8459990
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg i.v. 0, 4 and 8 h following chemotherapy)
Study: 8459990
Drug: Metoclopramide (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (3 mg/kg i.v. followed by an infusion of 0.5 mg/kg/h for 8 h)
Study: 8459990
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg) with dexamethasone (16 mg) before chemotherapy followed by oral dosing with 8 mg ondansetron 3 times daily for 5 days
Study: 8459990
Drug: Metoclopramide (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (60 mg) with dexamethasone (16 mg) before chemotherapy followed by oral dosing with 20 mg metoclopramide 3 times daily for 5 days
Study: 8459990
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg) given orally twice daily
Study: 3816928
Drug: Intravenous ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ceftriaxone 1 g
Study: 3816928
Drug: Intraperitoneal ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal ceftriaxone 1 g
Study: 2468447
Drug: 5% albumin
Normalized name: Flexbumin 5% Albumin (Human) Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% albumin infusion
Study: 22614886
Drug: Early antiretroviral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early antiretroviral therapy (ART) initiated before 3 months of age
Study: 11836563
Drug: 5'-DFUR treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5'-DFUR treatment for 6 months
Study: 8677154
Drug: Plasma antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma antioxidant activity (AOA) during clinical treatment (induction of chemotherapy, surgery, radiotherapy, maintenance chemotherapy)
Study: 2186259
Drug: Veramex 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veramex 80 (80 mg non-retarded Verapamil)
Study: 2186259
Drug: Reference substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference substance (80 mg non-retarded Verapamil)
Study: 386125
Drug: Cimetidine, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine, 1 g daily over eight weeks